Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 40% Undervaluation?

Simply Wall StDec 10 20:42

H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57

Futu NewsDec 10 19:31 · Ratings

Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data From Cancer Drug Study

MT NewswiresDec 10 02:32

Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...

BenzingaDec 10 01:07

B.Riley Financial Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $27

Futu NewsDec 7 03:31 · Ratings

Rigel Pharmaceuticals Is Maintained at Neutral by B. Riley Securities

Dow JonesDec 7 01:57 · Ratings